Bayer eyes wider use for Xarelto with new trials

FRANKFURT, Mar 9:  Bayer has initiated two new late-stage studies to widen the use of its anti-blood-clotting pill Xarelto, one of its most important new drugs. The German company, which is developing the pill with US peer Johnson & Johnson, said it would start a Phase III clinical trial to test Xarelto in patients with chronic heart failure and significant coronary artery disease. (agencies)


Please enter your comment!
Please enter your name here